An Evaluation of Antidiabetic Potential ofMethanolic Extractof Swertia Chirata in Streptozotocin Induced Diabetic rats

The present study evaluates the antidiabetic activity of Swertia chirata (methanolic extract) on the blood glucose level of streptozotocin induced diabetic rat models. To study the antidiabetic activity of methanolic extract of Swertia chirata in streptozotocin induced diabetes in albino rats. To compare the antidiabetic activity of Swertia chirata extract with that of standard drug glibenclamide used in the treatment of type 2 diabetes mellitus. In the present study 24 male albino wistar rats divided into 4 groups with 6 animals in each group was taken. One group as control was given normal saline for 21 days daily. Other 3 groups were induced diabetes. Standard and test groups were fed with glibenclamide (0.5mg/kg) and methanolic extract (50mg/kg) daily for 21 days respectively. The results were analysed with ANOVA (Analysis of Variance) and comparison with standard, test and control groups done by post hoc tukeys test. p< 0.001 was considered highly significant. An analysis of results shows that methanolic extract group (M3) of Swertia chirata have significant antidiabetic activity in comparison to respective control groups (M1, M2) but less marked antidiabetic activity when compared to the standard glibenclamide group (M4). Methanolic Extract of Swertiachirata at a dose of 50 mg/kg body weight has exhibited antidiabetic activity in streptozotocin induced diabetes in rats but exhibits less marked antidiabetic activity when compared to standard drug glibenclamide.